期刊文献+

cN0甲状腺微小乳头状癌中央区淋巴结转移数目>5枚危险因素分析 被引量:2

Risk factors for central lymph nodes more than 5 involved in papillary thyroid microcarcinoma with cN0
原文传递
导出
摘要 目的探讨临床淋巴结阴性(clinical lymph node negative,cN0)甲状腺微小乳头状癌(papillary thyroid microcarcinoma,PTMC)中央区淋巴结转移(central lymph node metastasis,CLNM)数目>5枚的危险因素。方法回顾性分析2013年1月至2018年12月重庆医科大学附属第一医院内分泌乳腺外科接受手术治疗的单侧cN0 PMTC患者1567例,男405例,女1162例。根据患侧CLNM分为0~5枚组和>5枚组并通过非参数检验、χ^(2)检验等比较两组性别、年龄等临床病理学特征。结果本研究患者CLNM>5枚为4.1%(65/1567)。单因素分析显示男、年龄≤50岁、肿瘤直径>8 mm、多灶癌与cN0 PTMC CLNM>5枚相关(P<0.05);多因素Logistic回归分析显示男(OR=1.886,P=0.017)、年龄≤50岁(OR=3.778,P=0.002)、肿瘤直径>8 mm(OR=2.483,P<0.001)、多灶癌(OR=2.362,P=0.005)为CLNM>5枚的独立危险因素。亚组分析显示喉前淋巴结转移≥1枚(OR=13.475,P<0.001)、气管前淋巴结转移≥2枚(OR=41.695,P<0.001)、喉前+气管前淋巴结转移≥2枚(OR=28.750,P<0.001)为CLNM>5枚的独立危险因素。结论单侧cN0 PTMC患者的CLNM>5枚与多种因素有关,男性、年龄≤50岁且存在肿瘤直径>8 mm、多灶癌的患者出现较多数量淋巴结转移风险增加,此类患者不建议长期随访观察,应积极手术治疗且行预防性中央区淋巴结清扫,并结合术中情况必要时选择全甲状腺切除。 Objective To analyze the risk factors of the number of central lymph node metastasis(CLNM)>5 in papillary thyroid microcarcinoma(PTMC)with clinical lymph node negative(cN0).Methods A total of 1567 cases of unilateral cN0 PTMC patients undergoing surgery at Endocrine and Breast Surgery Department of the First Affiliated Hospital of Chongqing Medical University from Jan.2013 to Dec.2018 were analyzed retrospectively.There were 405 cases of male and 1162 cases of female among them.According to the CLNM,they were divided into 0-5 and≥5 groups.Clinicopathological characteristics of two groups were compared with Chi-square test andχ^(2) test,et al.Results The case of CLNM>5 involved was 4.1%(65/1567).Univariate analysis showed that male,age≤50 years old,tumor diameter>8 mm,multifocal cancer all were related to CLNM>5 involved(P<0.05),multivariate logistic regression analysis found that male(OR=1.886,P=0.017),age≤50 years(OR=3.778,P=0.002),tumor diameter>8 mm(OR=2.483,P<0.001)and multifocal cancer(OR=2.362,P=0.005)were independent risk factors for CLNM>5.Subgroup analysis showed that the number of Delphian lymph nodes metastasis≥1(OR=13.475,P<0.001),pretracheal lymph nodes metastasis≥2(OR=41.695,P<0.001),and Delphian+pretracheal lymph nodes metastasis≥2(OR=28.750,P<0.001)were also independent risk factors for CLNM>5.Conclusions Unilateral PTMC patients who are male and age≤50 years old with tumor diameter>8 mm,multifocal cancer have higher risk of central lymph nodes more than 5 involved,surgical treatment and prophylactic central neck dissection are recommended to such patients instead of long-term follow-up observation.Total thyroidectomy should be selected appropriately according to the intraoperative situation.
作者 俞萍 邓畅 胡代星 黄春 王媛媛 舒秀洁 苏新良 Yu Ping;Deng Chang;Hu Daixing;Huang Chun;Wang Yuanyuan;Shu Xiujie;Su Xinliang(Department of Breast and Thyroid Surgery,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China;Department of General Surgery,the Seventh People’s Hospital of Chongqing,Chongqing 400054,China;Department of Breast and Thyroid,the Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)
出处 《中华内分泌外科杂志》 CAS 2022年第4期426-430,共5页 Chinese Journal of Endocrine Surgery
关键词 甲状腺微小乳头状癌 甲状腺癌 中央区淋巴结转移 中央区淋巴结清扫 Papillary thyroid microcarcinoma Thyroid carcinoma Central lymph nodes metastasis Central neck dissection
  • 相关文献

参考文献2

二级参考文献53

  • 1American Thyroid Association (ATA) Guidelines Taskforce on Thy- roid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association manage- ment guidelines for patients with thyroid nodules and differentiat- ed thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
  • 2Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid as- sociation management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid as- sociation guidelines task force on thyroid nodules and differentiat- ed thyroid cancer[J]. Thyroid, 2016, 26(1):1-133.
  • 3Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2.2014[J]. J Natl Compr Canc Netw, 2014, 12(12):1671-1680.
  • 4Xing MZ. Molecular pathogenesis and mechanisms of thyroid can- cer[J]. Nat Rev Cancer, 2013, 13(3):184-199.
  • 5De Biase D, Gandolfi G, Ragazzi M, et al. TERT promoter mutations in papillary thyroid microcarcinomas[J]. Thyroid, 2015, 25(9):1013- 1019.
  • 6Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients[J]. World J Surg, 2010, 34(1):28-35.
  • 7Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid [J]. Thyroid, 2003, 13(4):381-387.
  • 8Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer[J]. J Clin Oncol, 2015, 33(1):42-50.
  • 9Jiang LH, Chen C, Tan Z, et al. Clinical characteristics related to central lymph node metastasis in cN0 papillary thyroid carcinoma: a retro- spective study of 916 patients[J]. Int J Endocrinol, 2014, 2014:385787.
  • 10Ito Y, Fukushima M, Higashiyama T, et al. Tumor size is the strongest predictor of microscopic lymph node metastasis and lymph node recurrence of NO papillary thyroid carcinoma[J]. Endocr J, 2013, 60 (1):113-117.

共引文献409

同被引文献20

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部